By Daniella Parra
Haystack Oncology and Lisata Therapeutics (Nasdaq: LSTA) are jointly researching the efficacy of a pancreatic cancer therapy, they said.
The study will test Lisata’s drug, certepetide, combined with chemotherapy in patients with metastatic pancreatic cancer and Haystack’s technology will measure ctDNA levels in patients to analyze the early therapeutic effect of certepetide, they said.
“A significant challenge in the development of anti-cancer therapies for pancreatic tumors is the early measurement of response to treatment. Most clinical trials evaluating pancreatic cancer require waiting for long-term survival outcomes to discern treatment effect,” said Kristen K. Buck, M.D., Executive Vice President of R&D and Chief Medical Officer of Lisata. “Conventional response assessment via imaging may lack sensitivity in certain situations, and highly sensitive ctDNA assays offer the potential to quickly identify clinically meaningful biologic activity in difficult to treat cancers.
Contact:
Editor@executives-edge.com
